Differential response to zinc-induced apoptosis in benign prostate hyperplasia and prostate cancer cells

被引:24
|
作者
Yan, Michelle [1 ]
Hardin, Karin [1 ]
Ho, Emily [1 ,2 ]
机构
[1] Oregon State Univ, Dept Nutr & Exercise Sci, Corvallis, OR 97331 USA
[2] Oregon State Univ, Linus Pauling Inst Sci & Med, Corvallis, OR 97330 USA
来源
JOURNAL OF NUTRITIONAL BIOCHEMISTRY | 2010年 / 21卷 / 08期
关键词
Apoptosis; Benign prostate Hyperplasia; Cancer; Prostate; Zinc; MITOCHONDRIAL APOPTOGENESIS; CITRATE METABOLISM; CASPASE-3; ACTIVITY; NUTRITIONAL-STATUS; EPITHELIAL-CELLS; SUPPLEMENT USE; BCL-2; PROTEIN; NECK-CANCER; EXPRESSION; RISK;
D O I
10.1016/j.jnutbio.2009.04.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Zinc Concentrations in the prostate are uniquely high but are dramatically decreased with prostate cancer. Studies have suggested that increasing zinc in the prostate may be a potential therapeutic strategy. The goal of this study was to evaluate the antiproliferative effects of zinc in prostate cancer cells (PC-3) and noncancerous benign prostate hyperplasia (BPH) cells (BPH-1) and to define possible mechanisms. PC-3 and BPH-1 cells were treated with zinc (0-250 mu M) for 24 and 48 h, and cell growth and viability were examined. Apoptosis was assessed by phosphatidylserine externalization, caspase activation and protein expression of B-cell CLL/Iymphoma 2 (Bcl-2)-associated X protein (BAX):Bcl-2. BPH-1 cells were more sensitive to the antiproliferative effects of zinc compared to PC-3. The response to zinc in PC-3 and BPH-1 cells differed as evidenced by opposing effects on Bcl-2:BAX expression. Additionally, different effects on the nuclear expression and activity of the p65 subunit of nuclear factor kappa B were observed in response to zinc between the two cell types. The differential response to zinc in PC-3 and BPH-1 cells suggests that zinc may serve an important role in regulating cell growth and apoptosis in prostate cancer and hyperplasia cells. Published by Elsevier Inc.
引用
收藏
页码:687 / 694
页数:8
相关论文
共 50 条
  • [31] Baldness, benign prostate hyperplasia, prostate cancer and androgen levels
    Faydaci, Goekhan
    Bilal, Eryildirim
    Necmettin, Penpeguel
    Fatih, Tarhan
    Asuman, Orcun
    Ugur, Kuyumcuoglu
    AGING MALE, 2008, 11 (04): : 189 - 192
  • [32] Prostate inflammation Association with benign prostatic hyperplasia and prostate cancer
    Abdel-Meguid, Taha A.
    Mosli, Hisham A.
    Al-Maghrabi, Jaudah A.
    SAUDI MEDICAL JOURNAL, 2009, 30 (12) : 1563 - 1567
  • [33] Adipocytokine levels in benign prostate hyperplasia and prostate cancer patients
    Kosova, F.
    Temeltas, G.
    Muezzinoglu, T.
    Ari, Z.
    FEBS JOURNAL, 2016, 283 : 85 - 85
  • [34] Expression and significance of clusterin in normal prostate, benign prostate hyperplasia and prostate cancer
    周利群
    ChinaMedicalAbstracts, 2003, (02) : 121 - 122
  • [35] Zinc status in benign prostatic hyperplasia and prostate carcinoma
    Wiwanitkit, Somsri
    Wiwanitkit, Viroj
    INDIAN JOURNAL OF UROLOGY, 2012, 28 (01) : 115 - 115
  • [36] Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia
    Kyprianou, N
    Litvak, JP
    Borkowski, A
    Alexander, R
    Jacobs, SC
    JOURNAL OF UROLOGY, 1998, 159 (06): : 1810 - 1815
  • [37] BENIGN PROSTATE HYPERPLASIA
    VAHLENSIECK, W
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1986, 111 (04) : 154 - 155
  • [38] Benign prostate hyperplasia
    Kim, Hyung-Jee
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2015, 58 (10): : 878 - 885
  • [39] Benign prostate hyperplasia
    Droupy, S.
    PROGRES EN UROLOGIE, 2011, 21 : 3 - 5
  • [40] BENIGN PROSTATE HYPERPLASIA
    SCHONBERGER, B
    ZENTRALBLATT FUR CHIRURGIE, 1986, 111 (10): : 569 - 588